Source
BioSpace
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including:
- By Month 1, numerically fewer cumulative cardiovascular events, including CVM or recurrent CVH, were observed with acoramidis compared to placebo
- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30
- A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30
- Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK, Switzerland, Japan, and Brazil that all have a label specifying near-complete stabilization (≥90%)
News Url